Oculis Holding AG (OCS)
19.53
-0.05 (-0.26%)
At close: Mar 03, 2025, 3:59 PM
19.54
0.05%
After-hours: Mar 03, 2025, 04:00 PM EST
No 1D chart data available
| Bid | 19.06 |
| Market Cap | 937.44M |
| Revenue (ttm) | 824.17K |
| Net Income (ttm) | -88.01M |
| EPS (ttm) | -1.85 |
| PE Ratio (ttm) | -10.56 |
| Forward PE | -14.19 |
| Analyst | Buy |
| Ask | 22.07 |
| Volume | 27,549 |
| Avg. Volume (20D) | 73,798 |
| Open | 19.85 |
| Previous Close | 19.58 |
| Day's Range | 19.50 - 19.84 |
| 52-Week Range | 10.55 - 23.08 |
| Beta | 0.01 |
About OCS
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye ...
Industry Biotechnology
Sector Healthcare
IPO Date May 18, 2021
Employees 36
Stock Exchange NASDAQ
Ticker Symbol OCS
Website https://oculis.com
Analyst Forecast
According to 5 analyst ratings, the average rating for OCS stock is "Buy." The 12-month stock price forecast is $29, which is an increase of 48.49% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Oculis Holding AG is scheduled to release its earnings on Mar 17, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
+18.1%
Oculis shares are trading higher after the company...
Unlock content with
Pro Subscription
6 months ago
+0.51%
Oculis Holding shares are trading higher after the company reported Q2 financial results.
